Advaxis, Inc. (NASDAQ:ADXS) reported earnings for the three months ended April 2016 on June 08, 2016. The company earned $-0.45 per share on revenue of $0M. Analysts had been modeling earning per share of $-0.54 with $0M in revenue.
Advaxis, Inc. (NASDAQ:ADXS) announced dose administration for the first patient in the first stage of its Phase 2 clinical trial of their FAWCETT study, testing the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic anal cancer.
The multi-center, open-label, two-stage study is designed to evaluate the efficacy and safety of AXAL as a monotherapy in patients with HPV-associated metastatic anal cancer who have received at least one prior treatment regimen for the advanced disease. Stage 1 of the trial will enroll 31 patients with anal cancer whose disease recurred after receiving treatment. Patients will receive AXAL 1×109 colony forming unit (CFU) doses every three weeks for up to two years.
In collaboration with Brown University Oncology Research Group, AXAL has been evaluated in high-risk, locally advanced anal cancer with concurrent standard chemotherapy and radiation treatment. Preliminary data show treatment with AXAL indicated a clinical complete response and no recurrence in all 10 patients who completed the treatment regimen.
“The FAWCETT study is an important step in the development program for AXAL,” said Daniel J. O’Connor, President and Chief Executive Officer at Advaxis. “People living with anal cancer desperately need new treatment options, which is why Advaxis is pursuing two areas of evaluation, including monotherapy with AXAL and a second study with an immune checkpoint inhibitor in combination with AXAL.”
The FAWCETT (Fighting Anal-Cancer with CTL Enhancing Tumor Therapy) study was named in honor of Farrah Fawcett, who passed away due to HPV-associated anal cancer. In 2015, the Farrah Fawcett Foundation honored Advaxis with its inaugural “Medical Visionary Angel Award” based on the Company’s clinical research and efforts to treat this disease, initiating a partnership among the organizations.
Advaxis, Inc. earnings per share showed a decreasing trend of -73.7% for the current fiscal year. The company’s expected EPS decline rate for next fiscal year is -211%.Analysts project EPS decline over the next 5 years at 0%. It has EPS annual growth over the past 5 fiscal years of 28.5% when sales declined 0. It reported 0% sales drop, and 12.5% EPS growth in the last quarter.
The stock is trading at $8.17, up 56.81% from 52-week low of $5.21. The stock trades down -63.2% from its peak of $22.2 and % below the consensus price target of $22.5. Its volume clocked up at 0.62 million shares which is lower than the average volume of 0.78 million shares. Its market capitalization currently stands at $277.86M.